{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:01Z","timestamp":1787020801068,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen-Hong Kong Cooperation Zone for Technology and Innovation","award":["HZQB-KCZYB-2020056"],"award-info":[{"award-number":["HZQB-KCZYB-2020056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02182-8","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T23:03:38Z","timestamp":1766790218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2483-6717","authenticated-orcid":false,"given":"Jianyu","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4749-5987","authenticated-orcid":false,"given":"Limin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenru","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"6","key":"2182_CR1","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2182_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"2182_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"key":"2182_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061772","author":"S Greco","year":"2023","unstructured":"Greco S, Fabbri N, Spaggiari R, De Giorgi A, Fabbian F, Giovine A. Update on classic and novel approaches in metastatic triple-negative breast cancer treatment: a comprehensive review. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11061772.","journal-title":"Biomedicines"},{"key":"2182_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713497","author":"J Pang","year":"2023","unstructured":"Pang J, Li H, Zhang X, Luo Z, Chen Y, Zhao H, et al. Application of novel transcription factor machine learning model and targeted drug combination therapy strategy in triple negative breast cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713497.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2182_CR6","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460\u20137.","journal-title":"J Clin Oncol"},{"issue":"6013","key":"2182_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139.","journal-title":"Science"},{"key":"2182_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3389\/fimmu.2019.01415","volume":"10","author":"M Vitale","year":"2019","unstructured":"Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, et al. An historical overview: the discovery of how NK cells can kill enemies, recruit defense troops, and more. Front Immunol. 2019;10:1415.","journal-title":"Front Immunol"},{"issue":"19","key":"2182_CR9","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang F, Li J, Qi L, Liu D, Bo Y, Qin S, et al. A pan-cancer single-cell panorama of human natural killer cells. Cell. 2023;186(19):4235\u201351.","journal-title":"Cell"},{"issue":"5","key":"2182_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41576-019-0093-7","volume":"20","author":"T Stuart","year":"2019","unstructured":"Stuart T, Satija R. Integrative single-cell analysis. Nat Rev Genet. 2019;20(5):257\u201372.","journal-title":"Nat Rev Genet"},{"issue":"D1","key":"2182_CR11","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47(D1):D900\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2182_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44\u201356.","journal-title":"Nat Med"},{"issue":"22-23","key":"2182_CR13","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1093\/bioinformatics\/btaa1005","volume":"36","author":"K Huang","year":"2021","unstructured":"Huang K, Fu T, Glass LM, Zitnik M, Xiao C, Sun J. DeepPurpose: a deep learning library for drug-target interaction prediction. Bioinformatics. 2021;36(22\u201323):5545\u20137.","journal-title":"Bioinformatics"},{"issue":"6","key":"2182_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s43587-023-00415-z","volume":"3","author":"F Wong","year":"2023","unstructured":"Wong F, Omori S, Donghia NM, Zheng EJ, Collins JJ. Discovering small-molecule senolytics with deep neural networks. Nat Aging. 2023;3(6):734\u201350.","journal-title":"Nat Aging"},{"issue":"9","key":"2182_CR15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","volume":"34","author":"K Preuer","year":"2018","unstructured":"Preuer K, Lewis RPI, Hochreiter S, Bender A, Bulusu KC, Klambauer G. DeepSynergy: predicting anti-cancer drug synergy with deep learning. Bioinformatics. 2018;34(9):1538\u201346.","journal-title":"Bioinformatics"},{"issue":"15 Pt 1","key":"2182_CR16","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2182_CR17","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"issue":"3","key":"2182_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311.","journal-title":"Ann Oncol"},{"issue":"4","key":"2182_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479\u201389.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2182_CR20","first-page":"188593","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica et Biophysica Acta (BBA). 2021;1876(2):188593.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"5","key":"2182_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"key":"2182_CR22","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"2182_CR23","doi-asserted-by":"publisher","first-page":"1141047","DOI":"10.3389\/fimmu.2023.1141047","volume":"14","author":"Y Adib","year":"2023","unstructured":"Adib Y, Boy M, Serror K, Dulphy N, des Courtils C, Duciel L, et al. Modulation of NK cell activation by exogenous calcium from alginate dressings in vitro. Front Immunol. 2023;14:1141047.","journal-title":"Front Immunol"},{"issue":"4","key":"2182_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","volume":"65","author":"PS Becker","year":"2016","unstructured":"Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65(4):477\u201384.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2182_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835\u201347.","journal-title":"Nat Immunol"},{"key":"2182_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-13-0502-3_4","volume":"1068","author":"X Huang","year":"2018","unstructured":"Huang X, Liu S, Wu L, Jiang M, Hou Y. High throughput single cell RNA sequencing, bioinformatics analysis and applications. Adv Exp Med Biol. 2018;1068:33\u201343.","journal-title":"Adv Exp Med Biol"},{"key":"2182_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","volume":"39","author":"X Ren","year":"2021","unstructured":"Ren X, Zhang L, Zhang Y, Li Z, Siemers N, Zhang Z. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol. 2021;39:583\u2013609.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2182_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cac2.12078","volume":"40","author":"S Ding","year":"2020","unstructured":"Ding S, Chen X, Shen K. Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun. 2020;40(8):329\u201344.","journal-title":"Cancer Commun"},{"issue":"8","key":"2182_CR29","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.cell.2023.01.035","volume":"186","author":"K Swanson","year":"2023","unstructured":"Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J. From patterns to patients: advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell. 2023;186(8):1772\u201391.","journal-title":"Cell"},{"issue":"1","key":"2182_CR30","first-page":"41","volume":"15","author":"S Huang","year":"2018","unstructured":"Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteomics. 2018;15(1):41\u201351.","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"2182_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","volume":"39","author":"T Moser","year":"2023","unstructured":"Moser T, Kuhberger S, Lazzeri I, Vlachos G, Heitzer E. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 2023;39(4):285\u2013307.","journal-title":"Trends Genet"},{"issue":"2","key":"2182_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.7150\/ijbs.55716","volume":"17","author":"Z Peng","year":"2021","unstructured":"Peng Z, Wang Y, Wang Y, Jiang S, Fan R, Zhang H, et al. Application of radiomics and machine learning in head and neck cancers. Int J Biol Sci. 2021;17(2):475\u201386.","journal-title":"Int J Biol Sci"},{"issue":"7639","key":"2182_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature21056","volume":"542","author":"A Esteva","year":"2017","unstructured":"Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115\u20138.","journal-title":"Nature"},{"key":"2182_CR34","doi-asserted-by":"publisher","first-page":"749673","DOI":"10.3389\/fonc.2021.749673","volume":"11","author":"Y Guan","year":"2021","unstructured":"Guan Y, Zhu X, Liang J, Wei M, Huang S, Pan X. Upregulation of HSPA1A\/HSPA1B\/HSPA7 and downregulation of HSPA9 were related to poor survival in colon cancer. Front Oncol. 2021;11:749673.","journal-title":"Front Oncol"},{"issue":"24","key":"2182_CR35","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1158\/0008-5472.CAN-11-1409","volume":"71","author":"H Guo","year":"2011","unstructured":"Guo H, Deng Q, Wu C, Hu L, Wei S, Xu P, et al. Variations in HSPA1B at 6p21.3 are associated with lung cancer risk and prognosis in Chinese populations. Cancer Res. 2011;71(24):7576\u201386.","journal-title":"Cancer Res"},{"issue":"6960","key":"2182_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nature02055","volume":"425","author":"AJ Mungall","year":"2003","unstructured":"Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, et al. The DNA sequence and analysis of human chromosome 6. Nature. 2003;425(6960):805\u201311.","journal-title":"Nature"},{"key":"2182_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-020-09280-z","volume":"17","author":"D Shin","year":"2020","unstructured":"Shin D, Park J, Han D, Moon JH, Ryu HS, Kim Y. Identification of TUBB2A by quantitative proteomic analysis as a novel biomarker for the prediction of distant metastatic breast cancer. Clin Proteomics. 2020;17:16.","journal-title":"Clin Proteomics"},{"key":"2182_CR38","doi-asserted-by":"publisher","first-page":"e924343","DOI":"10.12659\/MSM.924343","volume":"26","author":"Y Jin","year":"2020","unstructured":"Jin Y, Zhang S, Liu L. Circular RNA circ_C16orf62 suppresses cell growth in gastric cancer by miR-421\/Tubulin beta-2A chain (TUBB2A) axis. Med Sci Monit. 2020;26:e924343.","journal-title":"Med Sci Monit"},{"issue":"1","key":"2182_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jcb.29925","volume":"123","author":"MW Baeken","year":"2022","unstructured":"Baeken MW, Behl C. On the origin of BAG(3) and its consequences for an expansion of BAG3\u2019s role in protein homeostasis. J Cell Biochem. 2022;123(1):102\u201314.","journal-title":"J Cell Biochem"},{"issue":"27","key":"2182_CR40","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.1073\/pnas.1007088107","volume":"107","author":"N Volakakis","year":"2010","unstructured":"Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, Silvaggi J, et al. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci U S A. 2010;107(27):12317\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2182_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/ng.3459","volume":"48","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67\u201373.","journal-title":"Nat Genet"},{"issue":"47","key":"2182_CR42","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.3748\/wjg.v18.i47.6865","volume":"18","author":"YF Han","year":"2012","unstructured":"Han YF, Cao GW. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol. 2012;18(47):6865\u201373.","journal-title":"World J Gastroenterol"},{"issue":"47","key":"2182_CR43","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1038\/s41388-021-02027-6","volume":"40","author":"L Kyjacova","year":"2021","unstructured":"Kyjacova L, Saup R, Ronsch K, Wallbaum S, Dukowic-Schulze S, Foss A, et al. IER2-induced senescence drives melanoma invasion through osteopontin. Oncogene. 2021;40(47):6494\u2013512.","journal-title":"Oncogene"},{"key":"2182_CR44","doi-asserted-by":"publisher","first-page":"1610504","DOI":"10.3389\/pore.2022.1610504","volume":"28","author":"M Zhou","year":"2022","unstructured":"Zhou M, Chen Y, Gu X, Wang C. A comprehensive bioinformatic analysis for identification of myeloid-associated differentiation marker as a potential negative prognostic biomarker in non-small-cell lung cancer. Pathol Oncol Res. 2022;28:1610504.","journal-title":"Pathol Oncol Res"},{"key":"2182_CR45","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13181","author":"M Li","year":"2024","unstructured":"Li M, Du Y, Zhang X, Zhou W. Research advances of MAL family members in tumorigenesis and tumor progression (review). Mol Med Rep. 2024. https:\/\/doi.org\/10.3892\/mmr.2024.13181.","journal-title":"Mol Med Rep"},{"issue":"4","key":"2182_CR46","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1021\/acs.jproteome.6b00618","volume":"16","author":"M Wen","year":"2017","unstructured":"Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, et al. Deep-learning-based drug-target interaction prediction. J Proteome Res. 2017;16(4):1401\u20139.","journal-title":"J Proteome Res"},{"issue":"Suppl 7","key":"2182_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-5031-0","volume":"19","author":"L Xie","year":"2018","unstructured":"Xie L, He S, Song X, Bo X, Zhang Z. Deep learning-based transcriptome data classification for drug-target interaction prediction. BMC Genomics. 2018;19(Suppl 7):667.","journal-title":"BMC Genomics"},{"issue":"11","key":"2182_CR48","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.2174\/0929867327666200907141016","volume":"28","author":"K Abbasi","year":"2021","unstructured":"Abbasi K, Razzaghi P, Poso A, Ghanbari-Ara S, Masoudi-Nejad A. Deep learning in drug target interaction prediction: current and future perspectives. Curr Med Chem. 2021;28(11):2100\u201313.","journal-title":"Curr Med Chem"},{"key":"2182_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.compbiolchem.2019.03.016","volume":"80","author":"J You","year":"2019","unstructured":"You J, McLeod RD, Hu P. Predicting drug-target interaction network using deep learning model. Comput Biol Chem. 2019;80:90\u2013101.","journal-title":"Comput Biol Chem"},{"issue":"18","key":"2182_CR50","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1007\/s00253-023-12661-7","volume":"107","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yang S, Li Z, Wu Y, Tang J, Feng M, et al. High-titer production of staurosporine by heterologous expression and process optimization. Appl Microbiol Biotechnol. 2023;107(18):5701\u201314.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"2182_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40001-019-0365-x","volume":"24","author":"M Malsy","year":"2019","unstructured":"Malsy M, Bitzinger D, Graf B, Bundscherer A. Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway. Eur J Med Res. 2019;24(1):5.","journal-title":"Eur J Med Res"},{"issue":"2","key":"2182_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1053\/j.seminhematol.2021.02.005","volume":"58","author":"K Ishitsuka","year":"2021","unstructured":"Ishitsuka K. Diagnosis and management of adult T-cell leukemia\/lymphoma. Semin Hematol. 2021;58(2):114\u201322.","journal-title":"Semin Hematol"},{"issue":"1","key":"2182_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12885-018-4224-x","volume":"18","author":"X Ai","year":"2018","unstructured":"Ai X, Mao F, Shen S, Shentu Y, Wang J, Lu S. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2\/PPARgamma\/PTEN\/mTOR signaling pathway. BMC Cancer. 2018;18(1):407.","journal-title":"BMC Cancer"},{"issue":"1","key":"2182_CR54","doi-asserted-by":"publisher","first-page":"11123","DOI":"10.1038\/s41598-022-15348-7","volume":"12","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Mitsuhashi A, Hongying P, Shioya M, Kojima K, Nishikimi K, et al. Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis. Sci Rep. 2022;12(1):11123.","journal-title":"Sci Rep"},{"issue":"11","key":"2182_CR55","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"2182_CR56","doi-asserted-by":"publisher","first-page":"101333","DOI":"10.1016\/j.artd.2024.101333","volume":"26","author":"AWR Burns","year":"2024","unstructured":"Burns AWR, Smith P, Lynch J. Intra-articular vancomycin reduces prosthetic infection in primary hip and knee arthroplasty. Arthroplasty Today. 2024;26:101333.","journal-title":"Arthroplasty Today"},{"issue":"8","key":"2182_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jacc.2023.12.016","volume":"83","author":"MJ Javorski","year":"2024","unstructured":"Javorski MJ, Rosinski BF, Shah S, Thompson MA, Streem D, Gordon SM, et al. Infective endocarditis in patients addicted to injected opioid drugs. J Am Coll Cardiol. 2024;83(8):811\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"5-6","key":"2182_CR58","first-page":"287","volume":"68","author":"I Demaret","year":"2013","unstructured":"Demaret I, Lemaitre A, Ansseau M. L\u2019h\u00e9ro\u00efne. Rev Med Liege. 2013;68(5\u20136):287\u201393.","journal-title":"Rev Med Liege"},{"issue":"1","key":"2182_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2004.03.172","volume":"22","author":"E Bruera","year":"2004","unstructured":"Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22(1):185\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2182_CR60","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2182_CR61","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551\u201369.","journal-title":"Molecules"},{"issue":"23","key":"2182_CR62","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/cmdc.202100473","volume":"16","author":"V Ciaffaglione","year":"2021","unstructured":"Ciaffaglione V, Modica MN, Pittala V, Romeo G, Salerno L, Intagliata S. Mutual prodrugs of 5-fluorouracil: from a classic chemotherapeutic agent to novel potential anticancer drugs. ChemMedChem. 2021;16(23):3496\u2013512.","journal-title":"ChemMedChem"},{"issue":"13","key":"2182_CR63","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"AU Buzdar","year":"2013","unstructured":"Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(13):1317\u201325.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2182_CR64","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.bbagen.2016.01.026","volume":"1860","author":"AA Thoppil","year":"2016","unstructured":"Thoppil AA, Choudhary S, Kishore N. Competitive binding of anticancer drugs 5-fluorouracil and cyclophosphamide with serum albumin: calorimetric insights. Biochim Biophys Acta. 2016;1860(5):917\u201329.","journal-title":"Biochim Biophys Acta"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02182-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:05:43Z","timestamp":1768485943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02182-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}